3 results match your criteria: "University of Florida Center for Regenerative Medicine[Affiliation]"
Activin A Is a Master Regulator of Phenotypic Switch in Adipose Stromal Cells Initiated by Activated Immune Cell-Secreted Interleukin-1β.
Stem Cells Dev
August 2024
Department of Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA.
Prolonged tissue ischemia and inflammation lead to organ deterioration and are often accompanied by microvasculature rarefaction, fibrosis, and elevated systemic Activin A (ActA), the level of which frequently correlates with disease severity. Mesenchymal stromal cells are prevalent in the perivascular niche and are likely involved in tissue homeostasis and pathology. This study investigated the effects of inflammatory cells on modulation of phenotype of adipose mesenchymal stromal cells (ASC) and the role of ActA in this process.
View Article and Find Full Text PDFDevelopment of a student-driven undergraduate program in regenerative medicine.
Regen Med
October 2022
University of Florida Center for Regenerative Medicine, Gainesville, FL 32610, USA.
Article Synopsis
- Regenerative medicine has the potential to transform healthcare but is underrepresented in undergraduate education.
- Two new courses have been created at a university through collaboration between students and faculty to address this gap.
- The program includes lectures from experts and is developing a certificate that combines coursework and research to help students pursue careers in regenerative medicine.
Cardiac stem cell therapy among Clinics of Uncertain Regulatory Status (COURS): under-regulated, under-observed, incompletely understood.
J Transl Med
July 2020
University of Florida Center for Regenerative Medicine, 1600 SW Archer Rd, PO Box 100277, Gainesville, FL, 32610-0277, USA.
Article Synopsis
- There is a significant amount of anecdotal and limited clinical trial information about cellular therapies, particularly in Florida, where many clinics offer these treatments without FDA approval.
- A survey of 8 clinics focused on "cell therapy for heart failure" revealed that over 20,000 patients have received treatment, with varying success rates, costs, and administration methods.
- The study recommends establishing a standardized data collection system and a public database for FDA-approved clinical trials to enhance patient care and transparency in the cardiovascular field.